Bailey Harville
Family · Statesboro, GANPI 1346974250
Payments from drug & device makers
Across 230 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$604
- Novo Nordisk$545
- AbbVie$485
- Amgen$332
- Boehringer Ingelheim$216
- Boston Scientific$215
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,766100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $604 |
| Novo Nordisk | 39 | $545 |
| AbbVie | 36 | $485 |
| Amgen | 24 | $332 |
| Boehringer Ingelheim | 13 | $216 |
| Boston Scientific | 13 | $215 |
| Lilly USA, LLC | 10 | $175 |
| Pfizer | 6 | $114 |
| Idorsia Pharmaceuticals US Inc | 6 | $107 |
| Medtronic | 6 | $96 |
| Exact Sciences | 6 | $91 |
| GSK | 5 | $87 |
| Esperion Therapeutics, Inc. | 6 | $85 |
| Corium, LLC | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Merck | 2 | $41 |
| Halozyme Inc | 2 | $38 |
| Lundbeck LLC | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Harmony Biosciences LLC | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Novartis | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
How this compares
$3,766 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 132 | $184,138 |
| OzempicSemaglutide | 117 | $164,364 |
| FarxigaDapagliflozin Propanediol | 107 | $113,361 |
| TrulicityDulaglutide | 70 | $96,108 |
| JardianceEmpagliflozin | 55 | $61,502 |
| EliquisApixaban | 68 | $61,127 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $54,884 |
| LinzessLinaclotide | 28 | $35,143 |
| VraylarCariprazine Hcl | 22 | $34,240 |
| VascepaIcosapent Ethyl | 41 | $23,797 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $23,622 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $23,352 |
| Diclofenac Sodium | 61 | $22,670 |
| RybelsusSemaglutide | 20 | $20,554 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $18,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $175 | $280,246202 claims |
| Novo NordiskOzempic, Rybelsus | $545 | $184,918137 claims |
| AstraZenecaFarxiga, Symbicort | $604 | $123,616143 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $216 | $94,93590 claims |
| AbbVieLinzess, Vraylar, Synthroid | $485 | $72,18788 claims |
| PfizerEliquis | $114 | $61,12768 claims |
| GSKTrelegy Ellipta | $87 | $23,62226 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $31 | $23,35228 claims |
| Johnson & JohnsonXarelto | $20 | $16,64820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Statesboro
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.